Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy - Full Text View

Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy

This study has been completed.

Sponsored by:	UCB
Information provided by:	UCB
ClinicalTrials.gov Identifier:	NCT00522522

Purpose

Naturalistic, multicentre, epidemiological study to evaluate the care services used during the process of diagnosis of any kind of epilepsy. Data about services since first seizure until confirmed diagnosis will be examined.

Condition

Epilepsy

Genetics Home Reference related topics:

pyridoxal 5'-phosphate-dependent epilepsy

MedlinePlus related topics:

Epilepsy

U.S. FDA Resources

Study Type:	Observational
Study Design:	Other, Retrospective

Official Title:	Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy Until Being Confirmed (EPILIVE Study)

Further study details as provided by UCB:

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	400
Study Start Date:	February 2008
Study Completion Date:	July 2008
Primary Completion Date:	July 2008 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	16 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients being diagnosed of any kind of EPILEPSY (criteria ILAE 2005) and with diagnosis being confirmed by a Neurologist over the last 6 months.

Criteria

Inclusion Criteria:

Patients of both sexes 16 years old or older, being diagnosed of any kind of EPILEPSY (criteria ILAE) and with diagnosis being confirmed by a Neurologist over the last 6 months and with write informed consent.

Exclusion Criteria:

Patients with epilepsy diagnosis confirmed by a Neurologist over the last 6 months before the study or with incapacity to fulfill the requirements of the study.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00522522

Locations


United States, Georgia
	UCB Pharma
	Smyrna, Georgia, United States

Sponsors and Collaborators

UCB

Investigators


Study Director:	UCB Clinical Trial Call Center	+1 877 822 9493 (UCB)

More Information

Responsible Party:	UCB ( Study Director )
Study ID Numbers:	N01292, EPILIVE
First Received:	August 27, 2007
Last Updated:	August 29, 2008
ClinicalTrials.gov Identifier:	NCT00522522
Health Authority:	Spain: Spanish Agency of Medicines

Keywords provided by UCB:

Naturalistic, retrospective, utilization of care services, diagnosis, epilepsy

Study placed in the following topic categories:

Epilepsy

Central Nervous System Diseases

Brain Diseases

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on October 10, 2008